Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 73, No. 3-4, 2007   

Free Abstract     Article (Fulltext)     Article (PDF 158 KB)     

Clinical Study

Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy
R. Largillier, B. Valenza, J.-M. Ferrero, C. Novo, A. Creisson, G. Lesbats, V. Mari, C. Hebert, E. Chamorey

Centre Antoine Lacassagne, Nice, France

Address of Corresponding Author

Oncology 2007;73:177-184 (DOI: 10.1159/000127384)


 goto top of page Key Words

  • Topotecan
  • Ovarian cancer

 goto top of page Abstract

Topotecan is indicated in the treatment of advanced-stage ovarian cancers refractory to prior platinum-based regimen. The aim of this study was to compare the standard therapeutic strategy with a novel strategy of weekly administration of topotecan. The primary endpoints were dose density and overall tolerance. This retrospective cohort study included patients with ovarian cancer in relapse. During a first period (1998-2001), 24 patients received the standard topotecan dose of 1.5 mg/m2/day for 5 consecutive days with a 3-week interval between each treatment course. During a second period (2003-2006), 21 patients received a weekly topotecan dose of 4 mg/m2 for 3 weeks out of every 4. Grades III and IV haematological toxicities were more frequent with the standard strategy (p < 0.05), even after adjustment of the prescription of erythropoietin and G-CSF. With the weekly strategy, an increase in dose density and a reduction in the number of delayed doses were observed. No significant difference between the 2 strategies was found in terms of response to the treatment and specific survival. This study suggests that the weekly administration of topotecan 4 mg/m2, for 3 weeks out of every 4, results in a better maintenance of dose density and a reduction in haematological toxicity.

Copyright © 2008 S. Karger AG, Basel


 goto top of page Author Contacts

E. Chamorey
Centre Antoine Lacassagne, 33, Avenue de Valombrose
FR-06189 Nice, Cedex 2 (France)
Tel. +33 4 92 03 15 29, Fax +33 4 93 81 71 31
E-Mail emmanuel.chamorey@nice.fnclcc.fr


 goto top of page Article Information

Received: September 6, 2007
Accepted after revision: September 12, 2007
Published online: April 16, 2008
Number of Print Pages : 8
Number of Figures : 2, Number of Tables : 6, Number of References : 29

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 18418010)
Download Citation

This journal is part of the fourth subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues

Case Reports in Oncology


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.





copyright  © 2009 S. Karger AG, Basel